Macrophage‐Mimicking Cellular Nanoparticles Scavenge Proinflammatory Cytokines in Specimens of Patients with Inflammatory Disorders

Effectively neutralizing inflammatory cytokines is crucial for managing a variety of inflammatory disorders. Current techniques that target only a subset of cytokines often fall short due to the intricate nature of redundant and compensatory cytokine networks. A promising solution to this challenge is using cell membrane‐coated nanoparticles (CNPs). These nanoparticles replicate the complex interactions between cells and cytokines observed in disease pathology, providing a potential avenue for multiplex cytokine scavenging. While the development of CNPs using experimental animal models has shown great promise, their effectiveness in scavenging multiple cytokines in human diseases has yet to be demonstrated. To bridge this gap, this study selected macrophage membrane‐coated CNPs (MФ‐CNPs) and assessed their ability to scavenge inflammatory cytokines in serum samples from patients with COVID‐19, sepsis, acute pancreatitis, or type‐1 diabetes, along with synovial fluid samples from patients with rheumatoid arthritis. The results show that MФ‐CNPs effectively scavenge critical inflammatory cytokines, including interleukin (IL)‐6, IL‐8, interferon (IFN)‐γ, and tumor necrosis factor (TNF)‐α, in a dose‐dependent manner. Overall, this study demonstrates MФ‐CNPs as a multiplex cytokine scavenging formulation with promising applications in clinical settings to treat a range of inflammatory disorders. Macrophage‐mimicking cellular nanoparticles (MФ‐CNPs) are fabricated and evaluated for multiplex scavenging of human proinflammatory cytokines ex vivo. It is demonstrated that MФ‐CNPs can effectively capture IL‐6, IL‐8, IFN‐γ, and TNF‐α in serum samples from patients with COVID‐19, sepsis, acute pancreatitis, and type‐1 diabetes, as well as synovial fluid samples from patients with rheumatoid arthritis.